Freya Biosciences ApS: Financial statements 2022
CVR: 41257547
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Freya Biosciences ApS (CVR 41257547) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -16,628,000 and a net result of DKK -32,157,000 compared with DKK -20,406,277 the year before. Equity in the 2022 report amounted to DKK -3,745,000.
- Gross Profit
- DKK -16,628,000
- Profit/Loss
- DKK -32,157,000
- Equity
- DKK -3,745,000
- Total Assets
- DKK 16,376,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -16.6 mio. | -32.2 mio. | -3.7 mio. | - |
| 2021 | 0 | -5.5 mio. | -20.4 mio. | 28.4 mio. | - |
Official annual report
Keep an eye on Freya Biosciences ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Freya Biosciences ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -20,406,277.
About Freya Biosciences ApS
Freya Biosciences ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2020. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Colleen Denise Acosta. The board consists of Peter Finsel Bisgaard (chair), Claudia Maria Colciago, Colleen Denise Acosta and David Lawrence Stern. The company's owners include Danmarks Eksport- og Investeringsfond, OMX Ventures Fund I, LLC and Sofinnova Capital IX. The company has 18 employees (2026). In 2025, the company reported a gross profit of DKK -14,130,000 and a net result of DKK -92,714,000 compared with DKK -85,434,294 the year before. Equity in the 2025 report amounted to DKK 72,025,000.